Amarin Corp. (AMRN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/18/2026
- Wall St futures bounce back as US-Iran deal optimism balances hawkish Fed; Intel up
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- US chip stocks gain after Apple-Intel partnership
- After-Hours Stock Movers: SWBI, SB, LPA, STLD, SPCX
- UniQure, Aehr Test Systems surge premarket; Snap, Leidos fall
- SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall
- Micron, Nebius surge premarket; Traws Pharma tumbles
- After-Hours Stock Movers: ADBE, MRVL, RH, RKLB, RDW, SPCE, ASTS
Amarin Reports Second Quarter 2023 Financial Results
August 2, 2023 7:11 AM EDT-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11 Million is Non-Cash --
-- Delivered Positive Cash Flow of $9 Million in the Quarter with a Cash Position of $313 Million --
-- Comprehensive Cost Reduction Plan Implemented in July with Expected Savings of $40 Million Over 12 Months--
-- Received Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain --
... More